Form 8-K Karyopharm Therapeutics For: Aug 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Karyopharm Therapeutics (KPTI) Moves to Session Lows
August 10, 2015 2:00 PM EDTKaryopharm Therapeutics (NASDAQ: KPTI) has moved to session lows following Q2 results reported before markets opened Monday. Shares are down over 39 percent and reached a 52-week low at $13.36 today. Volume at over 1.7 million shares compares with average daily volume of about 335,000 shares.
KPTI... More
Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c
August 10, 2015 7:41 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $150 thousand versus the consensus estimate of $90 thousand.
Financial Outlook
Based on current operating plans, Karyopharm expects that its existing... More
